📣 VC round data is live. Check it out!
- Public Comps
- Co-Diagnostics
Co-Diagnostics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Co-Diagnostics and similar public comparables like Nestmedic, Bio-Gate, Sds Optic, Bluelinea and more.
Co-Diagnostics Overview
About Co-Diagnostics
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Founded
2013
HQ

Employees
115
Website
Financials (LTM)
Market Cap
$9M
Valuation Multiples
Start free trialCo-Diagnostics Financials
Co-Diagnostics reported last 12-month revenue of $622K.
In the same LTM period, Co-Diagnostics generated had net loss of ($47M).
Revenue (LTM)
Co-Diagnostics P&L
In the most recent fiscal year, Co-Diagnostics reported revenue of $622K and EBITDA of ($30M).
Co-Diagnostics is unprofitable as of last fiscal year, with gross margin of 64%, EBITDA margin of (4848%), and net margin of (7534%).
Financial data powered by Morningstar, Inc.
Co-Diagnostics Stock Performance
Co-Diagnostics has current market cap of $9M.
Market Cap Evolution
Co-Diagnostics' stock price is $2.53.
Co-Diagnostics share price increased by 63.2% in the last 30 days.
Co-Diagnostics has an EPS (earnings per share) of $-13.02.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $9M | 0.0% | 63.2% | 10.0% | — | $-13.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCo-Diagnostics Valuation Multiples
Co-Diagnostics trades at (2.5x) EV/Revenue multiple, and 0.1x EV/EBITDA.
EV / Revenue (LTM)
Co-Diagnostics Financial Valuation Multiples
As of May 10, 2026, Co-Diagnostics has market cap of $9M.
Co-Diagnostics has a P/E ratio of (0.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Co-Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Co-Diagnostics Margins & Growth Rates
In the most recent fiscal year, Co-Diagnostics reported gross margin of 64%, EBITDA margin of (4848%), and net margin of (7534%).
Co-Diagnostics Margins
Co-Diagnostics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Co-Diagnostics Operational KPIs
Co-Diagnostics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Co-Diagnostics Competitors
Co-Diagnostics competitors include Nestmedic, Bio-Gate, Sds Optic, Bluelinea, iXensor, Subgen AI, Neola Medical, AMA Corp, PharmaCyte Biotech and Zynex.
Most Co-Diagnostics public comparables operate across Medical Devices, Laboratory Services, HealthTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 32.6x | — | (10.3x) | — | |||
| 1.0x | 0.9x | (5.3x) | (12.1x) | |||
| 44.2x | — | (25.0x) | — | |||
| 1.0x | — | 16.6x | — | |||
| 9.7x | — | (6.6x) | — | |||
| 0.6x | — | (13.4x) | — | |||
| 8.7x | 8.6x | (7.7x) | (7.5x) | |||
| 2.7x | — | (1.1x) | — | |||
This data is available for Pro users. Sign up to see all Co-Diagnostics competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Co-Diagnostics
| When was Co-Diagnostics founded? | Co-Diagnostics was founded in 2013. |
| Where is Co-Diagnostics headquartered? | Co-Diagnostics is headquartered in United States. |
| How many employees does Co-Diagnostics have? | As of today, Co-Diagnostics has over 115 employees. |
| Who is the CEO of Co-Diagnostics? | Co-Diagnostics' CEO is Dwight H Egan. |
| Is Co-Diagnostics publicly listed? | Yes, Co-Diagnostics is a public company listed on Nasdaq. |
| What is the stock symbol of Co-Diagnostics? | Co-Diagnostics trades under CODX ticker. |
| When did Co-Diagnostics go public? | Co-Diagnostics went public in 2017. |
| Who are competitors of Co-Diagnostics? | Co-Diagnostics main competitors include Nestmedic, Bio-Gate, Sds Optic, Bluelinea, iXensor, Subgen AI, Neola Medical, AMA Corp, PharmaCyte Biotech, Zynex. |
| What is the current market cap of Co-Diagnostics? | Co-Diagnostics' current market cap is $9M. |
| What is the current revenue of Co-Diagnostics? | Co-Diagnostics' last 12 months revenue is $622K. |
| What is the current EV/Revenue multiple of Co-Diagnostics? | Current revenue multiple of Co-Diagnostics is (2.5x). |
| Is Co-Diagnostics profitable? | No, Co-Diagnostics is not profitable. |
| What is the current net income of Co-Diagnostics? | Co-Diagnostics' last 12 months net income is ($47M). |
| How many companies Co-Diagnostics has acquired to date? | Co-Diagnostics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Co-Diagnostics has invested to date? | Co-Diagnostics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Co-Diagnostics
Lists including Co-Diagnostics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.